MedTrace Logo

Anticholinergic Burden - Treatment Optimization

NCT03208569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 663

Last updated 2025-08-28

No results posted yet for this study

Summary

There is increasing evidence that medications with anticholinergic effects may adversely impact cognitive function. Older adults are particularly sensitive to these effects due to age-related changes in pharmacokinetics and pharmacodynamics. The cumulative impact of taking one or more medications with anticholinergic properties is known as the anticholinergic burden. To quantify this burden, Boustani et al. (2008) developed the Anticholinergic Cognitive Burden (ACB) scale. The objective of this study is to examine whether optimizing pharmacotherapy concerning drugs with anticholinergic effects-identified by both the ACB scale and the newly developed Swe-ABS-can improve cognitive test performance among individuals attending a memory clinic. Anticholinergic drug use and cognitive performance will be assessed at baseline and at a 6-month follow-up.

Conditions

  • Anticholinergics
  • Cognitive Function

Sponsors & Collaborators

  • Angelholm Hospital

    collaborator OTHER

  • Region Skane

    lead OTHER

Principal Investigators

  • Per Johansson, MD, PhD · Region Skåne

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03208569 on ClinicalTrials.gov